• KOLs Community
    • Liver
    • Liver Cirrhosis
    • Jolanta Białkowska
    • Jolanta Białkowska

      Jolanta Białkowska

      Department of Infectious and Liver Diseases, Medical University of Lodz, 90-419 Lodz, Poland;, jolanta.e.bialkowska@gmail.com | Department of Infectious and Liver Diseases, ...



      KOL Resume for Jolanta Białkowska


      Department of Infectious and Liver Diseases, Medical University of Lodz, 90-419 Lodz, Poland;,


      Department of Infectious and Liver Diseases, Medical University of Lodz, Łódź, Poland


      Department of Infectious and Liver Diseases, Medical University of Lodz, Poland


      Department of Infectious and Liver Diseases, Medical University of Łódź, Łódź, Poland, .


      Lodz Poland


      Department of Infectious and Liver Diseases, Medical University of Lodz, Lodz, Poland



      Jolanta Białkowska: Influence Statistics

      Sample of concepts for which Jolanta Białkowska is among the top experts in the world.
      Concept World rank
      exposure infectious material #8
      impact comedications #14
      33 158 patients #14
      established online tool #14
      comedications virologic #14
      modification obv #14
      primary amber study #19
      cured hcv patients #19
      realworld interferonfree therapy #19
      ritonavir±dasabuvir±ribavirin #20
      reduction hepatic stiffness #20
      virologic response improvement #20
      16 hepatologic centres #20
      hepatic function reduction #20
      follow 2yfu #20
      2yfu 4 #20
      hcv 5 years #21
      liver function reduction #22
      poland ribavirin #22
      minimal moderate fibrosis #23
      60 antihbc testing #23
      daa hbsag #23
      111 10152 patients #23
      reactivations daa #23
      2017 treatmentnaïve patients #23
      oprd genotype #23
      oprd 8 #23
      10152 chronic #23
      3067 hcv genotype #23
      6139 202 #23
      therapy oprd #23
      treated oprd #23
      oprd 8 weeks #23
      8 12weeks therapy #23
      low risk hbvreactivation #23
      nonadvanced hepatic fibrosis #23
      patients oprd #23
      hbvreactivation daa therapy #23
      virologic response risk #24
      data epiter2 #26
      epiter2 study #26
      69 presented comorbidities #26
      patients primary study #26
      data epiter2 study #26
      current therapy oprd #26
      epiter‐2 study #26
      efficacy evaluation report #26
      decompensation child #27
      dasabuvir oprd #27
      poland interferon #27


      Prominent publications by Jolanta Białkowska

      KOL-Index: 14523

      A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7). Adult subjects were randomized and treated (n = 191) with entecavir 1.0 mg or adefovir 10 mg daily for up to 96 weeks from the date of last subject randomization. Subjects were positive or negative for hepatitis B e antigen and experienced or naive for treatment with nucleos(t)ide analogues. The ...

      Known for Hepatic Decompensation | Entecavir Adefovir | Chronic Hepatitis | Hbv Dna | Nucleostide Analogues
      KOL-Index: 9684

      BACKGROUND: Virologic and safety outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) therapy have shown high sustained virologic response (SVR) rates and good tolerability in most patient populations in pre-registration studies.

      AIM: To confirm these clinical trial findings in the treatment of genotype 1 and 4 hepatitis C under real-world conditions.

      METHODS: Patients enrolled for treatment with OBV/PTV/r ± DSV ± RBV based on therapeutic ...

      Known for ± Ribavirin | Chronic Hepatitis | Liver Cirrhosis | Virologic Response | 12 Weeks
      KOL-Index: 6949

      We followed for 2 years patients treated with direct-acting agents (DAA) to assess long-term durability of virologic response, improvement of liver function, reduction in liver stiffness (LS) and risk of hepatocellular carcinoma (HCC). The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin. ...

      Known for Liver Function | Hepatocellular Carcinoma | Virologic Response | Hepatic Decompensation | 2 Years
      KOL-Index: 6194

      The aim of the EpiTer-2 study was to analyse patient characteristics and their medication for HCV infection in Poland at the beginning of the interferon-free era. Analysis of data of HCV infected patients treated during the initial period of availability of interferon-free regimens in Poland, who started therapy after 1 July 2015 and had available an efficacy evaluation report before 30 June 2017 was undertaken. A total of 2879 patients with chronic hepatitis C were entered, including ...

      Known for Hcv Infection | Chronic Hepatitis | Liver Cirrhosis | Genotype 1b | Patients Infected
      KOL-Index: 4838

      BACKGROUND: To evaluate the effectiveness and safety of ledipasvir/sofosbuvir (LDV/SOF)±ribavirin (RBV) regimen in a real-world setting.

      METHODS: Patients received a fixed-dose combination tablet containing LDV and SOF with or without RBV, for 8, 12 or 24 weeks. Patients were assessed at baseline, end of treatment, and 12 weeks after the end of treatment. The primary effectiveness endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12).

      RESULTS: Of the 86 ...

      Known for Hcv Infection | Viral Load | 12 Weeks | Safety Sofosbuvir | Baseline Treatment
      KOL-Index: 4237

      BACKGROUND: Heart rhythm turbulence (HRT) is a novel tool for evaluation of cardiovascular mortality. Liver cirrhosis is associated with hemodynamic and myocardial disturbances termed cirrhotic cardiomyopathy. In the stable stage of liver cirrhosis, systolic and myocardial dysfunction is correlated with brain natriuretic peptide (BNP). The aim was to evaluate HRT and its correlation with NT-proBNP, echocardiographic and biochemical parameters in patients with decompensation of liver ...

      Known for Liver Cirrhosis | Cirrhotic Cardiomyopathy | Turbulence Onset | Biochemical Parameters | Cardiovascular Mortality
      KOL-Index: 4130

      OBJECTIVES: The aim of the study was to analyze the prevalence and clinical characteristics of HCV/HBV coinfection and to evaluate the rate of HBV-reactivation during anti-HCV therapy in a large real-world study.

      METHODS: Analyzed population consisted of 10,152 chronic hepatitis C patients treated with DAA between 2015 and 2019 in a nationwide study. Prior to the DAA all subjects had HBsAg and 60% anti-HBc testing.

      RESULTS: 111 of 10,152 patients (1.1%) had detectable HBsAg and 1239 of ...

      Known for Hbv Reactivation | Hepatitis Patients | Therapy Hcv | Antiviral Agents | Virus Activation
      KOL-Index: 3386

      The aim of the study is to analyze treatments available for patients infected with genotype (G) 3 hepatitis C virus (HCV) in Poland at the beginning of the interferon (IFN)-free era and evaluate the efficacy and safety of different therapeutic options administered in a real-world setting. We analyzed data of 198 patients who started antiviral therapy after July 1, 2015, and completed it before December 31, 2016; 57.6% of them had liver cirrhosis and 46% were treatment experienced. Fifty ...

      Known for Genotype 3 | Therapeutic Options | Svr Rate | Liver Cirrhosis | Realworld Setting

      Key People For Liver Cirrhosis

      Top KOLs in the world
      Williams Williams
      liver transplantation fulminant hepatic failure hepatocellular carcinoma
      Andrew Kenneth BURROUGHS
      liver transplantation primary biliary cirrhosis hepatocellular carcinoma
      Guadalupe Garcia‐Tsao
      portal hypertension patients cirrhosis variceal hemorrhage
      V Vallejos Arroyo∥
      hepatorenal syndrome cirrhotic rats patients cirrhosis
      Pere Ginès
      hepatorenal syndrome patients cirrhosis renal failure
      JOAN Rodés∥
      portal hypertension hepatocellular carcinoma cirrhotic rats

      Jolanta Białkowska:Expert Impact

      Concepts for whichJolanta Białkowskahas direct influence:Liver cirrhosis,  Chronic hepatitis,  Hepatic decompensation,  Virologic response,  Hcv infection,  Genotype 1b,  Ribavirin treatment,  Liver function.

      Jolanta Białkowska:KOL impact

      Concepts related to the work of other authors for whichfor which Jolanta Białkowska has influence:Chronic hepatitis,  Antiviral therapy,  Hepatocellular carcinoma,  Liver cirrhosis,  Hepatic decompensation,  Hcv genotype,  Virologic response.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Infectious and Liver Diseases, Medical University of Lodz, 90-419 Lodz, Poland;, jolanta.e.bialkowska@gmail.com | Department of Infectious and Liver Diseases, Medical University of Lodz, Łódź, Poland | Department of Infectious and Liver

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.